Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of endothelin receptor antagonism in treatment of coronary artery spasm (EDIT-CAS)
2023-507782-25-00Phase 3Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Coronary vasospasm (CAS) and coronary functional abnormalities (CFA) comparing Bosentan with Placebo (2 arms). Primary endpoint: Absence of epicardial vasospasm at 10 weeks. Planned start Sep 2024; status: authorised.
02
Drugs
bosentan
03
Conditions
Coronary vasospasm (CAS)coronary functional abnormalities (CFA)
Beyond the preview
Go deeper on 2023-507782-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507782-25-00.